Home Biosimilar Antibodies JAK/STAT EGFR Panitumumab (anti-EGFR)
For research use only. Not for use in humans.

Panitumumab (anti-EGFR)

Synonyms: ABX-EGF

Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).

Panitumumab (anti-EGFR)

3 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: Purity: 99% Protein concentration: 5.595mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation EGFR/ErbB1 HER2/ErbB2 ErbB3 ErbB4 mutant EGFR Others
Saracatinib (AZD0530) 312 c-Src,c-YES,LCK
Canertinib (CI-1033) 51
AG-490 132 JAK2 (V617F)
CP-724714 109
WZ4002 34
Sapitinib (AZD8931) 50
CUDC-101 23 HDAC,HDAC1,HDAC6
AG-1478 100
PD153035 HCl 20
Pelitinib (EKB-569) 11 Src,MEK/ERK,Raf
AEE788 (NVP-AEE788) 16 c-Abl,FLT1,c-Fms
AC480 (BMS-599626) 12
AP26113-analog (ALK-IN-1) 5 ALK,IGF1R,INSR
WZ3146 2
Allitinib tosylate 19
Rociletinib (CO-1686) 37
Varlitinib 8
Icotinib (BPI-2009H) 11
TAK-285 5 MEK1,Aurora B,LCK
WHI-P154 11 Src,VEGFR,JAK3
Daphnetin 4 PKA,PKC
PD168393 6
CNX-2006 2
Tyrphostin 9 2 PDGFR
AG-18 1
Icotinib Hydrochloride 0
HS-10296 hydrochloride 3
MTX-531 0 PI3Kα
Avitinib maleate 0 BTK
limertinib 0
AG 825 0 PDGFR
4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 1
AST-1306 10
ErbB2 inhibitor 0
Tuxobertinib (BDTX-189) 3 RIPK2,BLK
Epertinib hydrochloride 1
JND3229 0 EGFR C797S
BI-4020 1
Tyrphostin AG-528 0
AG 556 0
Canertinib dihydrochloride 8
EGFR Inhibitor 4 Microtubules
SU5214 0 VEGFR2
RG 13022 0
TQB3804 1
zipalertinib (TAS6417) 5 TXK,BMX
Pyrotinib dimaleate 6
PD153035 14
AG 494 0
AG 555 1
Theliatinib (HMPL-309) 0
Avitinib (Abivertinib) 3 JAK3,BTK
Lazertinib (YH25448) 9 Del19,L85R
Lifirafenib (BGB-283) 8 WT A-RAF,C-RAF (Y340/341D),BRAF(V600E)
Nazartinib (EGF816) 6
Zorifertinib (AZD3759) 7
CL-387785 (EKI-785) 5
Poziotinib (NOV120101, HM781-36B) 37
AZ5104 6 ACK1,BLK,BRK
AV-412 free base 0
HER2-Inhibitor-1 1
WZ8040 3
Genistein 38 topo II
Rezivertinib 1
BDTX-1535 0
Falnidamol 1
BLU-945 1
(S)-Sunvozertinib ((S)-DZD9008) 1
CH7233163 1
Licochalcone D 1 NF-κB,PARP,Caspase
Furmonertinib Mesylate (AST2818, Alflutinib) 3 CYP3A4
(Rac)-JBJ-04-125-02 0
Tyrphostin AG30 (AG30) 0
AG-1557 0
AG99 0
MTX-211 2 PI3K
RG14620 0 ABCG2
Almonertinib (HS-10296) 4
Cyasterone 1
Norcantharidin 5 c-Met
Naquotinib(ASP8273) 2
EAI045 3
Olmutinib (BI 1482694) 6 BTK
Butein 3
Chrysophanic Acid 3 mTOR
EGCG ((-)-Epigallocatechin Gallate) 42 DNMT,telomerase,FASN
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).
References

Product Details

CAS No. 339177-26-3
Molecular Weight 144 kD
Isotype Human IgG2
Source CHO cells
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07544992 RECRUITING Recurrent Astrocytoma, IDH-Mutant, Grade 4; Recurrent Glioblastoma, IDH-Wildtype City of Hope Medical Center 2026-05-26 PHASE1
NCT07741643 NOT_YET_RECRUITING Drug: Panitumumab-IRDye800|Drug: [18F]NOTA-ABY-030 HNSCC,Larynx, Pharynx and Oral Cavity; Squamous Cell Carcinoma; Head and Neck Cancer; Head and Neck Surgery Vanderbilt-Ingram Cancer Center 2026-08 PHASE1
NCT07318883 NOT_YET_RECRUITING Drug: HLX07|Drug: HLX07 placebo|Drug: Serplulimab|Drug: Pemb Squamous NSCLC Shanghai Henlius Biotech 2026-03 PHASE2; PHASE3
NCT04511078 RECRUITING Drug: Panitumumab-IRDye800 Head and Neck Cancer University of Alabama at Birmingham 2021-04-02 PHASE2
NCT05564377 RECRUITING Drug: Alpelisib|Drug: Binimetinib|Drug: Fluorouracil|Drug: F Advanced Malignant Solid Neoplasm; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Locally Advanced Malignant Solid Neoplasm; Malignant Female Reproductive System Neoplasm; Metastatic HER2-Negative Breast Carcinoma; Metastatic Malignant Solid Neoplasm; Recurrent Endometrial Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma; Unresectable HER2-Negative Breast Carcinoma; Unresectable Malignant Solid Neoplasm National Cancer Institute (NCI) 2023-04-07 PHASE2
NCT07124884 NOT_YET_RECRUITING Drug: Administration of experimental treatment association ( Colorectal Carcinoma; KRAS G12C Mutation; Unresectable Colorectal Cancer Federation Francophone de Cancerologie Digestive 2025-08-31 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.